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meta-analysisAbstract Background: Recent trials have suggested that maintenance treatments improve
outcomes for patients not progressing after ﬁrst-line therapy for advanced non-small-cell lung
cancer (NSCLC). However, physicians have little guidance on selecting which patients beneﬁt
the most and what drug or regimen is optimal. Here, we report a systematic review and net-
work meta-analysis of maintenance treatments in subgroups determined by performance sta-
tus (PS), epidermal growth factor receptor (EGFR) mutation, histology and response to
induction.
Methods: PubMed and conference proceedings were reviewed and individual study relative
efﬁcacy measures were meta-analysed in a Bayesian hierarchical model. The primary outcome,
overall survival (OS), was evaluated in terms of (i) posterior surface under cumulative ranking
curve (SUCRA), (ii) probability of being best treatment, (iii) probability of outperforming not Drive,
P.S. Tan et al. / European Journal of Cancer 51 (2015) 2330–2344 2331maintenance, and (iv) posterior median hazard ratio (95% credible interval). Secondary out-
comes were progression-free survival (PFS) and adverse events.
Findings: Twelve trials evaluating eight maintenance treatments in 3850 patients were
meta-analysed. Selected maintenance treatments showed clinically meaningful beneﬁts of
P20% reduction in hazards of death with P90% probability of outperforming no mainte-
nance in terms of OS: (i) switch to or continue pemetrexed (nonsquamous), continue gemc-
itabine, or switch to EGFR tyrosine kinase inhibitors (TKIs) for PS 0 patients, (ii) switch
to pemetrexed (nonsquamous) for PS 1 patients, (iii) switch to EGFR TKI for EGFR muta-
tion positive patients, (iv) switch to or continue pemetrexed or switch to EGFR TKI for non-
squamous patients, (v) continue gemcitabine for squamous patients, (vi) switch to docetaxel or
continue gemcitabine for responders to induction, or (vii) switch to or continue pemetrexed
(nonsquamous) or switch to EGFR TKI for patients with stable disease post-induction.
Interpretation: Maintenance treatments show clinically meaningful survival beneﬁts in good
performance status patients with advanced NSCLC not progressing after ﬁrst-line chemother-
apy. Beneﬁts are optimised by targeting speciﬁc maintenance to individual patients guided by
PS, EGFR mutation status, histology and response to induction.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lung cancer remains the most incident and fatal can-
cer in men worldwide [1]. In 2012, lung cancer con-
tributed to 1.6 million deaths worldwide with
mortality to incidence ratio of 0.8 [2]. In the US, patients
with metastatic non-small-cell lung cancer (NSCLC)
had 5-year survival <5% [3].
Standard ﬁrst-line therapies for advanced NSCLC
patients include 4–6 cycles of platinum doublet
chemotherapy [4,5]. In a recent meta-analysis, it
was shown that platinum doublet chemotherapy for
six cycles oﬀered no survival gain but rendered
greater toxicity in comparison with three or four cycles
[6].
In the palliative setting, only approximately 60% of
advanced NSCLC patients could proceed to receive
second-line therapy due to deteriorating clinical condi-
tion, suboptimal response to treatment or inadequate
insurance coverage [7–11]. Studies suggest early delivery
of eﬀective treatments during tumour regression
could eﬃciently kill tumour cells due to tumours’ sus-
ceptibility and lack of treatment resistance during this
time [12,13].
Recent maintenance trials have shown that patients
with disease control after ﬁrst-line induction therapy
may beneﬁt from maintenance therapies administered
before disease progression [8,10,14–19]. Trials investi-
gating switch to pemetrexed, geﬁtinib, erlotinib and doc-
etaxel, as well as continue gemcitabine and pemetrexed
showed progression free survival (PFS) beneﬁts in
patients with disease control post-induction [8,10,14–
18]. However, overall survival (OS) beneﬁts were less
pronounced, with only single trials demonstrating statis-
tically signiﬁcant survival gains for maintenance switch
to erlotinib and switch to pemetrexed in unselected pop-
ulations [8,16].Subgroup analyses suggest performance status (PS),
epidermal growth factor receptor (EGFR) mutation sta-
tus, histology and response to induction as potential
predictors of maintenance therapy beneﬁts [8,14–17],
although most trials were not powered for subgroup
analyses and made no accommodation for multiple
comparisons. Hence, there is a need to synthesise this
evidence and assess its consistency across trials.
Despite emerging evidence suggesting potential bene-
ﬁts of maintenance therapies [8,10,14–18], physicians
have little guidance on selecting which patients beneﬁt
the most and what drug or regimen is optimal. Hence,
there is a pressing need to (i) synthesise the information
contained in these trials to achieve a comprehensive sum-
mary of the best available evidence on potential beneﬁts
of maintenance therapies, and (ii) identify predictors of
treatment beneﬁt to aid in selecting patients expected to
beneﬁt from particular maintenance treatments.
In this study, we performed a systematic review and
network meta-analysis (NMA) of current evidence to
evaluate OS, PFS and adverse events (AE) in stage
IIIb/IV NSCLC patients with good performance status
not progressing after ﬁrst-line chemotherapy. We evalu-
ated eﬃcacy outcomes in a spectrum of clinically rele-
vant populations deﬁned by PS, EGFR mutation
status, histology and response to previous induction
for clinically meaningful beneﬁts [20].
Treatments were compared on the basis of surface
under the cumulative ranking curve (SUCRA), a sum-
mary estimate of treatment eﬃcacy used to rank com-
peting treatments, which is appropriate from a
decision making point of view, i.e. choosing the treat-
ment which evidence suggests is best [21]. In addition,
probability of being the best treatment, probability of
outperforming no maintenance and posterior median
hazard ratio for eﬃcacy outcomes along with credible
intervals are reported.
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2.1. Systematic review
PubMed was searched for phase II/III randomised
controlled trials published from 1st December 2003 to
14th October 2014 evaluating maintenance treatments
in stage IIIb/IV NSCLC patients not progressing after
ﬁrst-line chemotherapy. Additionally, the American
Society of Clinical Oncology 2014 (ASCO) and
European Society of Medical Oncology 2014 (ESMO)
meeting libraries were searched for relevant new evi-
dence [22,23].
Maintenance treatment was deﬁned as treatment
administered to non-progressing patients after ﬁrst-line
induction chemotherapy [12]. We included studies that
(i) evaluated maintenance treatments in patients ran-
domised after ﬁrst-line therapy [12,24], (ii) had at least
80% subjects with good PS: Eastern Cooperative
Oncology Group (ECOG) PS 0-1, World Health
Organisation (WHO) PS 0-1, or Karnofsky PS >80,
and (iii) were published in English. We excluded studies
that evaluated (i) surgical, radiation, chemoradiation,
intrapleural or distant-organ metastasis therapy (ii) sup-
portive treatments, (iii) complementary medicine, and
(iv) additional cycles of ﬁrst-line therapies continued
as maintenance and totalling less than six cycles over
induction and maintenance.
Two independent reviewers (PST, SA) performed
title, abstract and full-text screening. Final decisions
were reached through team consensus in the case of dis-
agreement. Two investigators (PST, SA) extracted data
for baseline trial and patient characteristics, eﬃcacy out-
comes (OS, PFS) and AEs (all grades and grade 3 or
worse). In the case of multiple publications on the same
trial, the most up-to-date evidence was used.2.2. Outcome evaluation
The primary outcome was OS, which we evaluated in
terms of (i) posterior SUCRA, (ii) probability of being
the best treatment, (iii) probability of outperforming
no maintenance, and (iv) posterior median hazard ratio
relative to no maintenance with respective 95% credible
interval. SUCRA provides a single summary estimate of
relative treatment eﬃcacy by taking the average of
cumulative rank probabilities of treatment k being
ranked r-th best among c treatments:
SUCRAk ¼
Pc1
r¼1probk;r
c1 . SUCRA values range from 0
(posterior certainty that treatment is the worst) to 1
(posterior certainty that treatment is the best) [21].
Secondary outcomes were PFS and adverse events. We
evaluated eﬃcacy outcomes in a spectrum of clinically
relevant populations deﬁned by PS, EGFR mutation
status, histology and response to induction for clinically
meaningful beneﬁts deﬁned by P20% reduction inhazards of death [20], withP90% probability of outper-
forming no maintenance in terms of OS. Treatment by
covariate interactions were also evaluated, comparing
eﬃcacy of maintenance treatments across PS 0 versus
PS 1, EGFR mutation positive versus wild-type, non-
squamous versus squamous and complete or partial
induction response (CR/PR) versus stable disease
(SD). Outcomes in the unselected population were also
evaluated.2.3. Statistical analysis
Relative eﬃcacies of treatments with respect to OS
and PFS were summarised in terms of hazard ratios
(HR) and meta-analysis was performed on the logarith-
mic scale. If a study [10,25] did not provide complete
information on hazard ratio estimates and their corre-
sponding standard errors, they were estimated using
methods proposed in Tierney et al. [26] Adverse event
rates were summarised separately for each treatment as
proportion of events per total safety evaluable popula-
tion along with Wilson conﬁdence intervals (CI) [27].
Tyrosine kinase inhibitors (TKIs) eﬀects were modelled
as a weighted average of the EGFR activating mutation
subpopulation relative eﬃcacy and EGFR wild-type
subpopulation relative eﬃcacy, with the reported eﬃca-
cies being for a population with a mutation rate between
typical Asian and Caucasian populations [15–17,28].
However, TKI eﬃcacy estimates for OS by PS, histol-
ogy, induction response and PFS by PS were not
weighted for EGFR mutation rates, as there were insuf-
ﬁcient individual studies estimates available to perform
such an analysis, and should be interpreted within the
context of TKI eﬀects in a predominantly Caucasian
population. For histology subgroup estimates, results
for studies reporting estimates in the nonsquamous
and adenocarcinoma subgroups were modelled together
(see detailed methods in the Appendix).
Individual studies HRs (OS and PFS) were modelled
on the logarithmic scale within a Bayesian network hier-
archical model, with reported treatment eﬃcacies cen-
tred around their corresponding mean and variance
components comprising of within-study and
between-study heterogeneity. Non-informative priors
were used for treatment eﬃcacy and a
weakly-informative prior was used for between-study
variances along with sensitivity analysis as suggested
by Turner et al. [29] The two relative eﬃcacy measures
in the three arm IFCT-GFPC 0502 [17] trial were mod-
elled as bivariate normal with marginal distributions
matching those described above and with a correlation
coeﬃcient, q. Posterior sampling was performed using
Markov Chain Monte Carlo with 10 chains of 500,000
iterations per chain, each with a burn-in of 500,000 iter-
ations. Using the posterior sample, SUCRA values,
probabilities of being best treatment, probabilities of
3768 records screened
175 records excluded: 
143 randomized before induction 
  11 review 
    5 no maintenance 
    4 quality of life studies 
    4 chemoradiation 
    3 not randomized controlled trials 
    2 ethnicity subgroup analyses 
    1 no relevant estimate 
    1 not stage IIIb/IV 
    1 prognostic study 
3574 ineligible records excluded
198 records included for 
detailed assessment 
4 records from other sources
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hazard ratios for eﬃcacy outcomes along with credible
intervals were used to compare maintenance treatments.
Constructing the model from a Bayesian perspective
allowed a natural incorporation of sources of uncer-
tainty and computation of posterior probabilities [21].
95% predictive intervals, which could be expected to
capture treatment eﬃcacies in a new study or setting,
were also computed. In addition, traditional pairwise
meta-analysis was performed as per DerSimonian and
Laird’s random eﬀects model [30] along with
study-to-study heterogeneity I2 statistics [31].
Bayesian NMA was performed using JAGS software
within R 3.0.2 and traditional pairwise meta-analysis
was performed using R 3.0.2 [32,33]. Detailed methods
are provided in Appendix.23 records (14 trials) included 
in systematic review 
19 records (12 trials) included 
in network meta-analysis  
4 records (2 trials)a with no common 
comparator arm within network
were excluded from meta-analysis 
Fig. 1. Search strategy diagram for trials evaluating maintenance
treatments in good performance status stage IIIb/IV non-small-cell
lung cancer (NSCLC) patients not progressing after ﬁrst-line induction
based on Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [34] guidelines. aAVAPERL [35,36] and ATLAS
[37,38] were not included in the network meta-analysis as there was no
common comparator arm with other included maintenance trials.3. Results
3768 records were screened and 12 trials evaluating
eight maintenance treatments in 3850 stage IIIb/IV
NSCLC patients were included in the NMA (Figs. 1
and 2). AVAPERL [35,36] and ATLAS [37,38] were
compared qualitatively with other maintenance trials,
but not included in the NMA for eﬃcacy analysis as
they did not share a common comparator arm with
the other included studies. Characteristics of included
studies are provided in Table 1 with details in
Appendix Tables A1–2.
Included subjects had good performance status
(approximately 45% PS 0, 55% PS 1), fair response to
induction (approximately 45% CR/PR, 55% SD) and
advanced disease (approximately 20% stage IIIb and
80% stage IV) as illustrated in Table 1 and Appendix
Table A2. While the inclusion criteria required studies
to contain at least 80% subjects with good PS, a few
studies had small proportions of subjects with PS >1
(Appendix Table A2). Subjects who did not progress
after platinum-doublet induction chemotherapy were
randomised to maintenance treatments until evidence
of progression or unacceptable toxicity, with the excep-
tion of Fidias et al. [10,25] which compared immediate
versus delayed docetaxel for a maximum of six cycles
after induction chemotherapy.3.1. Overall survival
Summary of OS eﬃcacy results focuses on mainte-
nance therapies with P20% reduction in hazard, and
P90% probability of outperforming no maintenance
in terms of OS.3.1.1. Performance status
In the PS 0 population, SUCRA for switch to peme-
trexed, continue pemetrexed, continue gemcitabine and
switch to EGFR TKI were 85.4%, 59.7%, 56.1% and45.5% respectively, with 63%, 18%, 15% and 4% proba-
bility respectively of being the best, and >99%, 96%,
95% and 97% posterior probability respectively of out-
performing no maintenance. Meta-estimates showed
substantial OS beneﬁt (deﬁned as P20% reduction in
hazard of death and P90% probability of outperform-
ing no maintenance in terms of OS) with all mainte-
nance treatments compared to no maintenance in
patients with PS 0 (Fig. 3, Table 2).
In the PS 1 population, SUCRA for switch to peme-
trexed was 67.3%, with 38% probability of being the
best, and 90% posterior probability respectively of out-
performing no maintenance. Meta-estimates showed
substantial OS beneﬁt with switch to pemetrexed com-
pared to no maintenance in patients with PS 1. No other
maintenance regimens compared here (switch to EGFR
TKI, continue pemetrexed or continue gemcitabine)
showed substantial OS beneﬁt in patients with PS 1.
Examination of treatment by PS interaction showed
that switch to pemetrexed, continue pemetrexed, and
continue gemcitabine had respectively 89%, 73% and
80% posterior probability to perform better relative to
no maintenance in PS 0 versus PS 1 populations
(Table 2). Eﬃcacies for pemetrexed regimens by PS were
synthesised from nonsquamous populations [9,39,46].
Fig. 2. Trials included in network meta-analysis evaluating maintenance treatments in good performance status stage IIIb/IV non-small-cell lung
cancer (NSCLC) patients not progressing after ﬁrst-line induction. Thicknesses of lines are proportional to the number of trials included in
analyses. aIFCT-GFPC 0502 [17] was a three-arm trial comparing switch to erlotinib, continue gemcitabine and no maintenance.
2334 P.S. Tan et al. / European Journal of Cancer 51 (2015) 2330–23443.1.2. EGFR mutation
In the EGFR mutation positive population, SUCRA,
probability of being the best, and probability of outper-
forming no maintenance for switch to EGFR TKI was
94.1%, as these measures are equivalent for the compar-
ison of only two treatments, EGFR TKI and no main-
tenance. In the EGFR wild-type population, SUCRA,
probability of being the best, and probability of outper-
forming no maintenance for switch to EGFR TKI was
88.3% (Fig. 3, Table 2).
Examination of treatment by EGFR mutation inter-
action showed that switch to EGFR TKI had 84% pos-
terior probability of performing better relative to no
maintenance in the EGFR mutation positive versus
EGFR wild-type population (Table 2). There was no
evidence of a diﬀerence between switch erlotinib and
switch geﬁtinib in either the EGFR mutant or
wild-type subpopulations (Appendix Table A3). At the
time of SATURN analysis, OS for EGFR mutation pos-
itive subjects was not mature with median survival not
reached, and authors reported extensive cross-over of
subjects receiving erlotinib upon progression (67%) [16].3.1.3. Histology
In the nonsquamous population, SUCRA for switch
to pemetrexed, switch to EGFR TKI and continue
pemetrexed were 76.6%, 60.5% and 56.1% respectively,
with 30%, 9% and 5% probability respectively of being
the best, and 99%, 98% and 96% posterior probability
respectively of outperforming no maintenance.
Meta-estimates showed substantial OS beneﬁt for switch
to pemetrexed, switch to EGFR TKI and continue
pemetrexed compared to no maintenance in the non-
squamous population (Fig. 4, Table 2).
In the squamous population, SUCRA for continue
gemcitabine was 88.4%, with 79% probability of being
the best, and 92% posterior probability of outperform-
ing no maintenance. Meta-estimates showed substantial
OS beneﬁt with continue gemcitabine compared to no
maintenance in the squamous population. No other
maintenance regimens compared here (switch toEGFR TKI or switch to pemetrexed) showed promising
activity in patients with squamous histology.
Examination of treatment by histology interaction
showed that switch pemetrexed and switch to EGFR
TKI had respectively 96% and 80% posterior probability
to perform better relative to no maintenance in non-
squamous versus squamous populations. On the con-
trary, continue gemcitabine had 84% posterior
probability of performing better relative to no mainte-
nance in squamous versus nonsquamous (Table 2).
3.1.4. Induction response
In the complete or partial response (CR/PR) popula-
tion, SUCRA for switch to docetaxel and continue gem-
citabine were 87.9% and 62.5% respectively, with 66%
and 15% probability respectively of being the best, and
99% and 94% posterior probability respectively of out-
performing no maintenance. Meta-estimates showed
substantial OS beneﬁt with switch to docetaxel and con-
tinue gemcitabine compared to no maintenance in
patients with CR/PR to induction (Fig. 4, Table 2).
In the stable disease (SD) population, SUCRA for
maintenance switch to pemetrexed, continue pemetrexed
and switch to EGFR TKI were 92.7%, 68.9% and 66.8%
respectively, with 75%, 16% and 6% probability respec-
tively of being the best, and >99%, 94% and 98% poste-
rior probability respectively of outperforming no
maintenance. Meta-estimates showed substantial OS
beneﬁt with switch to pemetrexed, continue pemetrexed
and switch to EGFR TKI compared to no maintenance
in subjects with SD post-induction.
Examination of treatment by induction response
interaction showed that switch to docetaxel and con-
tinue gemcitabine had respectively 96% and 87% poste-
rior probability of performing better relative to no
maintenance in CR/PR versus SD. On the contrary,
switch to pemetrexed and switch to EGFR TKI had
respectively 86% and 75% posterior probability of per-
forming better relative to no maintenance in SD versus
CR/PR (Table 2). Eﬃcacies for pemetrexed regimens
by induction response were synthesised from nonsqua-
mous populations [9,39,46].
Table 1
Characteristics of included studies comparing maintenance treatments in good performance status stage IIIb/IV NSCLC patients not progressing after ﬁrst-line chemotherapy.a
Study Population Induction Maintenance N Median follow-
up (months)
Switch to pemetrexed versus no maintenance
JMEN [8,39,40] Treatment-naı¨ve (systemic) stage
IIIb/IV NSCLC with ECOG PS
0-1 not progressing after
induction
Carboplatin or cisplatin/gemcitabine,
paclitaxel, or docetaxel (4 cycles)
Switch to pemetrexed 500 mg/m2 day 1 of
21-day cycles plus BSC
441 11.2
Placebo plus BSC 222 10.1
Switch to geﬁtinib versus no maintenance
INFORM; C-TONG 0804 [15,19] Treatment-naı¨ve stage IIIb/IV
NSCLC with WHO PS 0-2 not
progressing after induction
Platinum-doublet chemotherapy (4
cycles)
Switch to geﬁtinib 250 mg daily 148
17.8
Placebo 148
EORTC 08021/ILCP 01/03 [14] Treatment-naı¨ve stage IIIb/IV
NSCLC with WHO PS 0-2 not
progressing after induction
Platinum-containing chemotherapy
(median 4 cycles, range 2–6 cycles)
Switch to geﬁtinib 250 mg daily 86
41
Placebo 87
Switch to erlotinib versus no maintenance
SATURN [16,41,42] Treatment-naı¨ve recurrent or
stage IIIb/IV NSCLC with
ECOG PS 0-1 not progressing
after induction
Platinum-doublet chemotherapy (4
cycles)
Switch to erlotinib 150 mg daily 438 11.4
Placebo 451 11.5
IFCT-GFPC 0502 [17] Treatment-naı¨ve stage IIIb/IV
NSCLC with ECOG PS 0-1 not
progressing after induction
Cisplatin/gemcitabine (4 cycles) Switch to erlotinib 150 mg daily 155
25.6
Observation 155
Switch to sunitinib versus no maintenance
CALGB 30607 [43] Treatment-naı¨ve stage IIIb/IV
NSCLC with ECOG PS 0-1 not
progressing after induction
Platinum containing chemotherapy (4
cycles)
Switch to sunitinib 37.5 mg qd 106 –
Placebo 104 –
Switch to pazopanib versus no maintenance
EORTC 08092 [44] Treatment-naı¨ve advanced
NSCLC with ECOG PS 0-2 not
progressing after induction
Platinum containing chemotherapy (4–6
cycles)
Switch to pazopanib 800 mg daily 50 –
Placebo 52 –
Switch to docetaxel versus no maintenance
Fidias et al. [10,25] Chemo-naive stage IIIb/IV
NSCLC with ECOG PS 0-2 not
progressing after induction
Carboplatin/gemcitabine (4 cycles) Switch to immediate docetaxel 75 mg/m2
day 1 every 21-day cycle (maximum 6
cycles)
153 –
Delayed docetaxel 75 mg/m2 day 1 every
21-day cycle (maximum 6 cycles) at
progression
156 –
(continued on next page)
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Table 1 (continued)
Study Population Induction Maintenance N Median follow-
up (months)
Switch to docetaxel versus continue pemetrexed
Karayama et al. [45] Chemo-naive nonsquamous stage
IIIb/IV NSCLC with ECOG PS
0-1 not progressing after
induction
Carboplatin/pemetrexed (4 cycles) Switch to docetaxel 60 mg/m2 day 1 every
21-day cycle
25
16.8
Continue pemetrexed 500 mg/m2 day 1
every 21-day cycle
26
Continue pemetrexed versus no maintenance
PARAMOUNT [9,46,47] Chemo-naı¨ve nonsquamous stage
IIIb/IV NSCLC with ECOG PS
0-1 not progressing after
inductionb
Cisplatin/pemetrexed (4 cycles) Continue pemetrexed 500 mg/m2 day 1
every 21-day cycle plus BSC
359
12.5
Placebo plus BSC 180
Mubarak et al. [48] Treatment-naı¨ve (systemic)
nonsquamous stage IIIb/IV
NSCLC with ECOG PS 0-1 not
progressing after induction
Cisplatin/pemetrexed (4 cycles) Continue pemetrexed 500 mg/m2 every 21
days plus BSC
28 –
BSC 27
Continue gemcitabine versus no maintenance
IFCT-GFPC 0502 [17] Treatment-naı¨ve stage IIIb/IV
NSCLC with ECOG PS 0-1 not
progressing after inductionf
Cisplatin/gemcitabine (4 cycles) Continue gemcitabine 1250 mg/m2 days 1
and 8 every 21-days cycle
154
25.6
Observation 155
Brodowicz et al. [18] Chemo-naı¨ve stage IIIb/IV
NSCLC with Karnofsky PS >80
not progressing after inductionc
Cisplatin/gemcitabine (4 cycles) Continue gemcitabine 1250 mg/m2 days 1
and 8 every 21-days cycle plus BSC
66 20.5
BSC 33 17
Pemetrexed/bevacizumab versus bevacizumab alone
AVAPERL [35,36] Treatment-naı¨ve nonsquamous
recurrent or stage IIIb/IV
NSCLC with ECOG PS 0-1
Cisplatin/pemetrexed/bevacizumab
7.5 mg/kg (4 cycles)
Bevacizumab 7.5 mg/kg/pemetrexed
500 mg/m2 on day 1 of 21-days cycle
128
14.8
Bevacizumab 7.5 mg/kg on day 1 of 21-
days cycle
125
Erlotinib/bevacizumab versus bevacizumab alone
ATLAS [37,38] Treatment-naı¨ve recurrent or
stage IIIb/IV NSCLC with
ECOG PS 0-2
Chemotherapy/bevacizumab 15 mg/kg (4
cycles)
Bevacizumab 15 mg/kg on day 1 of 21-
days cycle/erlotinib 150 mg daily
370 8.5
Bevacizumab 15 mg/kg on day 1 of 21-
days cycle /placebo
373 8.3
a Maintenance treatments were continued in patients with complete response, partial response, or stable disease after induction until disease progression, unacceptable toxicity, and/or physician’s
decision to terminate, unless otherwise stated. Outcomes were measured from randomisation. Where multiple publications are available, most mature results were used.
b Included 3/539 patients with ECOG PS >1.
c Subgroup results of subjects with KPS >80 were used.N, sample size; BSC, best supportive care; PS, performance status; NSCLC, non-small-cell lung cancer; ECOG, Eastern Cooperative Oncology
Group; WHO, World Health Organisation.
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PS 0
favors maintenance
No Maintenance
Bayesian network 0.72 (0.46-1.07)
IFCT-GFPC-0502 0.65 (0.44-0.97)
Continue Gemcitabine
Bayesian network 0.70 (0.46-1.06)
PARAMOUNT 0.70 (0.50-1.02)
Continue Pemetrexedb
Bayesian network 0.77 (0.58-1.01)
Traditional pairwise, I2= 34.7% 0.76 (0.57-1.03)
Erlotinib, IFCT-GFPC-0502 0.63 (0.42-0.95)
Erlotinib, SATURN 0.86 (0.65-1.13)
Switch to EGFR TKIc
Bayesian network 0.57 (0.37-0.87)
JMEN 0.57 (0.40-0.83)
Switch to Pemetrexedb
  3.2%
56.1%
59.7%
45.5%
85.4%
SUCRAHR (95% CI)a
PS 1
favors maintenance
No Maintenance
Bayesian network 0.90 (0.64-1.32)
IFCT-GFPC-0502 0.97 (0.68-1.37)
Continue Gemcitabine
Bayesian network 0.82 (0.60-1.12)
PARAMOUNT 0.82 (0.64-1.03)
Continue Pemetrexedb
Bayesian network 0.83 (0.66-1.05)
Traditional pairwise, I2= 2.2% 0.82 (0.69-0.96)
Erlotinib, IFCT-GFPC-0502 0.96 (0.67-1.37)
Erlotinib, SATURN 0.78 (0.65-0.94)
Switch to EGFR TKIc
Bayesian network 0.80 (0.57-1.13)
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Fig. 3. Overall survival by Eastern Cooperative Oncology Group
(ECOG) performance status (PS) and epidermal growth factor
receptor (EGFR) mutation status for maintenance treatments in good
performance status stage IIIb/IV non-small-cell lung cancer (NSCLC)
patients not progressing after ﬁrst-line induction. Treatments were
compared to no maintenance. aBayesian network estimates reported as
hazard ratio (95% credible intervals in black and 95% predictive
intervals in red). bSwitch pemetrexed [39] and continue pemetrexed
[9,46] estimates were estimated from trials results within the nonsqua-
mous population. cTKI estimates by PS were in a predominantly
Caucasian population. TKI, tyrosine kinase inhibitors; HR, hazard
ratio.
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PFS beneﬁt was broadly consistent with OS beneﬁt
although more pronounced, with selected maintenance
treatments showing remarkable P99% probability ofoutperforming no maintenance. Detailed PFS ﬁndings
are provided in the Appendix.3.3. Combination maintenance therapy with bevacizumab
Combination maintenance with bevacizumab/peme-
trexed in AVAPERL [35,36] and bevacizumab/erlotinib
in ATLAS [37,38] versus bevacizumab suggested a trend
for OS beneﬁts with signiﬁcant PFS beneﬁts (Appendix
Tables A1–2). Similar to other EGFR TKI maintenance
trials, ATLAS [37,38] demonstrated the possibility of
substantial OS beneﬁt in the EGFR mutation positive
population (OS HR 0.46, 95% CI 0.21–1.02) versus
wild-type (OS HR 0.86, 95% CI 0.65–1.15).3.4. Adverse events
Maintenance chemotherapywas commonly associated
with haematologic events, with neutropenia frequently
seen with docetaxel (76%) and gemcitabine (42%), and
less common with pemetrexed (6–12%). Maintenance
EGFR TKI was commonly associated with skin and gas-
trointestinal adverse events, maintenance MKI was asso-
ciated with hypertension and maintenance bevacizumab
was associated with hypertension and haemorrhagic
events (Table 3, Appendix Tables A6–7).3.5. Additional and sensitivity analysis
SUCRA curves for competing maintenance treat-
ments are provided for OS in Fig. 5 and PFS in
Appendix Fig. A3. Results in the unselected population
are provided in Appendix Fig. A4 and Table A5.
Sensitivity analysis using Turner et al.’s s2 prior speciﬁ-
cation [29] showed qualitatively unchanged results
(Appendix Figs. A5–9, Tables A8–10).4. Discussion
Selected maintenance treatments show clinically
meaningful beneﬁts of P20% reduction in hazards of
death with P90% probability of outperforming no
maintenance in terms of OS, despite the majority of
included studies having approximately 40–90% of sub-
jects receiving post-discontinuation treatments upon
progression and up to 45% of subjects crossing over to
receive study drug (Appendix Table A2) [8,15–17,46].
Our meta-analysis suggests that it is important to
select speciﬁc maintenance for particular patient groups
for clinically meaningful beneﬁts [20]. Results suggest
the following strategy: (i) switch to or continue peme-
trexed (nonsquamous), continue gemcitabine, or switch
to EGFR TKI for PS 0 patients, (ii) switch to peme-
trexed (nonsquamous) for PS 1 patients, (iii) switch to
EGFR TKI for EGFR mutation positive patients, (iv)
switch to or continue pemetrexed or switch to EGFR
Table 2
Overall survival surface under the cumulative ranking curves (SUCRAs), posterior probabilities best, posterior probabilities of outperforming no maintenance, and hazard ratios by Eastern
Cooperative Oncology Group (ECOG) performance status (PS), epidermal growth factor receptor (EGFR) mutation status, histology, and induction response for maintenance treatments in good
performance status stage IIIb/IV non-small-cell lung cancer (NSCLC) patients not progressing after ﬁrst-line induction. Predictive probability estimates represent expected treatment eﬃcacies in a new
study or setting. Treatments by covariate interactions examine posterior probability of treatment eﬃcacies relative to no maintenance by patient subgroups.
Maintenance SUCRA, % (predictive)c Probability best
(predictive)c
Probability outperforming
no maintenance (predictive)c
Overall survival,
HR (95% CrI)
Treatment by covariate interactiond
ECOG PS 0 Probability better in PS 0 versus PS 1
Switch to pemetrexeda 85.4 (83.7) 0.63 (0.60) 1.00 (0.99) 0.57 (0.37–0.87) 0.89 (0.87); p = 0.149
Continue pemetrexeda 59.7 (59.3) 0.18 (0.19) 0.96 (0.94) 0.70 (0.46–1.06) 0.73 (0.71); p = 0.469
Continue gemcitabine 56.1 (55.9) 0.15 (0.16) 0.95 (0.93) 0.72 (0.46–1.07) 0.80 (0.77); p = 0.137
Switch to EGFR TKIb 45.5 (46.0) 0.04 (0.05) 0.97 (0.94) 0.77 (0.58–1.01) 0.65 (0.62); p = 0.707
No maintenance 3.2 (5.1) 0.00 (0.00) – 1.00 –
ECOG PS 1
Switch to pemetrexeda 67.3 (65.9) 0.38 (0.36) 0.90 (0.88) 0.80 (0.57–1.13) –
Switch to EGFR TKIb 63.8 (62.3) 0.20 (0.21) 0.95 (0.90) 0.83 (0.66–1.05) –
Continue pemetrexeda 63.2 (62.0) 0.29 (0.28) 0.90 (0.87) 0.82 (0.60–1.12) –
Continue gemcitabine 42.7 (43.8) 0.13 (0.14) 0.73 (0.71) 0.90 (0.64–1.32) –
No maintenance 13.0 (16.0) 0.00 (0.00) – 1.00 –
EGFR mutant Probability better in EGFR mutant versus wild-type
Switch to EGFR TKI 94.1 (93.3) 0.94 (0.93) 0.94 (0.93) 0.58 (0.29–1.16) 0.84 (0.83); p = 0.301
No maintenance 5.9 (6.7) 0.06 (0.07) – 1.00 –
EGFR wild-type
Switch to EGFR TKI 88.3 (84.4) 0.88 (0.84) 0.88 (0.84) 0.84 (0.64–1.13)
No maintenance 11.7 (15.6) 0.12 (0.16) – 1.00
Nonsquamous Probability better in nonsquamous versus squamous
Switch to pemetrexed 76.6 (74.7) 0.30 (0.29) 0.99 (0.98) 0.70 (0.52–0.94) 0.96 (0.94); p = 0.039
Switch to docetaxel 70.3 (69.9) 0.54 (0.53) 0.81 (0.81) 0.63 (0.22–1.80) –
Switch to EGFR TKIb 60.5 (59.4) 0.09 (0.10) 0.98 (0.95) 0.78 (0.62–0.99) 0.80 (0.75); p = 0.335
Continue pemetrexed 56.1 (55.7) 0.05 (0.07) 0.96 (0.93) 0.80 (0.62–1.04) –
Continue gemcitabine 23.1 (25.1) 0.01 (0.02) 0.59 (0.58) 0.96 (0.70–1.35) 0.16 (0.19); p = 0.429
No maintenance 13.4 (15.2) 0.00 (0.00) – 1.00 –
Squamous
Continue gemcitabine 88.4 (86.0) 0.79 (0.74) 0.92 (0.90) 0.74 (0.49–1.16) –
Switch to EGFR TKIb 56.6 (55.9) 0.13 (0.15) 0.78 (0.74) 0.91 (0.70–1.18) –
No maintenance 31.5 (32.8) 0.02 (0.02) – 1.00 –
Switch to pemetrexed 23.5 (25.3) 0.07 (0.08) 0.36 (0.37) 1.07 (0.72–1.58) –
Induction response CR/PR Probability better in CR/PR versus SD
Switch to docetaxel 87.9 (86.2) 0.66 (0.62) 0.99 (0.98) 0.61 (0.40–0.93) 0.96 (0.95); p = 0.044
Continue gemcitabine 62.5 (61.1) 0.15 (0.15) 0.94 (0.91) 0.77 (0.52–1.08) 0.87 (0.84); p = 0.081
Continue pemetrexeda 51.5 (51.3) 0.09 (0.10) 0.87 (0.85) 0.81 (0.56–1.17) 0.40 (0.41); p = 0.770
Switch to pemetrexeda 51.3 (51.1) 0.10 (0.11) 0.86 (0.84) 0.81 (0.55–1.19) 0.14 (0.17); p = 0.219
Switch to EGFR TKIb 37.9 (38.8) 0.01 (0.02) 0.89 (0.84) 0.87 (0.70–1.09) 0.25 (0.30); p = 0.317
No maintenance 9.0 (11.5) 0.00 (0.00) – 1.00 –
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itabine for squamous patients, (vi) switch to docetaxel
or continue gemcitabine for responders to induction,
or (vii) switch to or continue pemetrexed (nonsqua-
mous) or switch to EGFR TKI for patients with stable
disease post-induction.
Quality of life reported inmaintenance trials has shown
good tolerability of maintenance treatments in patients
not progressing after ﬁrst-line chemotherapy [10,49–52].
Nevertheless, it is worth considering that maintenance
with chemotherapy agent is associated with haematologic
toxicities (more with docetaxel, less with gemcitabine and
pemetrexed), EGFR TKI is associated with rash and
gastrointestinal toxicities, while bevacizumab is associ-
ated with hypertension and haemorrhage.
A limitation of this study is our inability to evaluate
combination bevacizumab maintenance in the eﬃcacy
analysis. Eﬃcacies in AVAPERL [35,36] and ATLAS
[37,38] were only evaluated qualitatively as there were
no common comparator arms with other maintenance
trials included in the NMA. Moreover, ﬁrst-line studies
which randomised subjects at induction and continued
treatments beyond ﬁrst-line chemotherapy were not
included as they involve both the induction and mainte-
nance risk process in addition to a two part treatment
[53–55]. Future work remains in evaluating optimal
ﬁrst-line with maintenance regimen combinations,
although a recent meta-analysis has shown ﬁrst-line
EGFR TKIs continued in the absence of disease pro-
gression to outperform chemotherapy in patients with
EGFR mutations [56]. Additionally, the analysis of
PS, EGFR mutation, histology and response to previous
induction’s impact on eﬃcacy has been limited to uni-
variate, or one variable at a time, which represents an
average impact across the other relevant covariates.
For a patient in which two or more prognostic covari-
ates are known, there may be conﬂicting evidence
depending on which covariate is considered, particularly
if the patient presents with an uncommon combination
of prognostic factors. This limitation reﬂects the status
of currently available evidence.
Our study is the ﬁrst NMA comparing maintenance
treatments for NSCLC which evaluates the impact of
performance status, EGFR mutation, histology and
induction response thus targeting patients with the
greatest beneﬁt from maintenance treatments after
ﬁrst-line chemotherapy. Further, probability statements
and rankings provided in speciﬁc clinical settings in our
meta-analysis aid clinical decision-making when select-
ing the best treatments for individual patients, without
being biased towards the no-maintenance option when
available evidence fails to reject the null hypothesis.
In conclusion, selected maintenance treatments
administered to good performance status patients with
non-progressing stage IIIb/IV NSCLC after ﬁrst-line
chemotherapy show clinically meaningful survival
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Fig. 4. Overall survival by histology and induction response for maintenance treatments in good performance status stage IIIb/IV non-small-cell
lung cancer (NSCLC) patients not progressing after ﬁrst-line induction. Treatments were compared to no maintenance. Estimate for switch
docetaxel in the nonsquamous population was an indirect comparison compared to no maintenance computed from Karayama et al. [45] which
compared switch docetaxel to continue pemetrexed. aBayesian network estimates reported as hazard ratio (95% credible intervals in black and 95%
predictive intervals in red). bTKI estimates by histology and induction response were in a predominantly Caucasian population. cSwitch pemetrexed
[39] and continue pemetrexed [9,46] estimates by induction response subgroups were estimated from trials results within the nonsquamous
population. CR/PR, complete or partial response to previous induction; SD, stable disease post-induction; TKIs, tyrosine kinase inhibitors; HR,
hazard ratio.
2340 P.S. Tan et al. / European Journal of Cancer 51 (2015) 2330–2344beneﬁts. Beneﬁts are optimised by targeting speciﬁc
maintenance to individual patients, guided by perfor-
mance status, EGFR mutation status, histology and
response to previous induction. Tolerability of mainte-
nance and patient preferences should also be considered
in treatment decisions.5. Contributors
GL conceived the research idea. PST, BH, MB, GL
and SA conceptualised the study design. PST and SA
screened studies and extracted information. PST, BH
and MB participated in data analysis and interpretation.
Table 3
Adverse event rates for all grades (grade 3 or worse reported in parenthesis) by maintenance treatment in good performance status stage IIIb/IV non-small-cell lung cancer (NSCLC) patients not
progressing after ﬁrst-line induction.
Adverse event Switch to
Pemetrexed
Switch to
geﬁtinib
Switch to
erlotinib
Switch to
sunitinib
Switch to
pazopanib
Switch to
docetaxel
Continue
pemetrexed
Continue
gemcitabine
Continue
bevacizumab
Pemetrexed/
bevacizumab
Erlotinib/
bevacizumab
No
maintenance
Any (0.16) 0.67 () 0.65 (0.13) – – – 0.43 (0.14) (0.28) 0.87 (0.31) (0.38) 0.96 (0.48) 0.21 (0.02)
AE leading to drug discontinuation 0.05 () 0.07 () 0.05 () 0.29 () 0.22 () 0.11 () 0.12 () – 0.12 () 0.18 () 0.17 () 0.02 ()
Leucopaenia 0.06 (0.02) 0.03 (0) – – – 0.80 (0.28) 0.07 (0.03) – – – – 0.01 (0)
Neutropenia 0.06 (0.03) (0.01) 0.03 (0.01) (0.06) (0.08) 0.76 (0.34) 0.12 (0.06) 0.42 (0.21) (0) (0.06) – 0.01 (0.03)
Thrombocytopenia – (0.01) 0.01 (0) (0.12) – 0.04 (0.01) 0.05 (0.02) 0.39 (0.06) (0) (0) – 0.01 (0)
Anaemia 0.15 (0.03) 0.03 (0) 0.15 (0.01) (0.06) – 0.56 (0.02) 0.20 (0.07) 0.38 (0.03) (0) (0.03) – 0.05 (0.01)
Alanine aminotransferase (ALT) 0.10 (0) 0.21 (0.05) – – (0.06) – 0.03 (0) – – – – 0.04 (0)
Aspartate aminotransferase (AST) 0.08 (0) 0.14 (0.03) – – – – 0.02 (0) – – – – 0.03 (0)
ALT/AST/aminotransferases – 0.05 (0.01) – – – 0.20 (0) 0.24 (0.08) – – – – 0.01 (0)
Investigations – 0.31 () – – – – – – – – – 0.14 ()
Alopecia – – – – – 0.64 (0) 0.12 (0) – – – – –
Anorexia/appetite loss 0.19 (0.02) 0.02 (0) 0.05 (0.01) – – – 0.05 (0) 0.07 (0.01) – – – 0.03 (0)
Fatigue/asthenia 0.24 (0.05) (0.05) 0.17 (0.01) (0.25) – 0.36 (0.10) 0.21 (0.04) – 0.08 (0.02) 0.14 (0.02) – 0.10 (0.02)
Infection/infection without neutropenia 0.05 (0.02) 0.08 (0.01) 0.05 (0.01) – – 0 (0) 0.12 (0.04) 0.06 (0.01) 0.25 (0.05) – 0.30 (0.05) 0.01 (0)
Febrile neutropenia – – – – – 0.12 (0.05) 0.02 (0.02) – – – – 0 (0.01)
Cardiovascular/chest pain – 0.02 (0) – – – – 0.11 (0) – 0.08 (0.02) – 0.08 (0.02) 0.04 (0.03)
Hypertension – – – (0.08) (0.38) – – – 0.22 (0.05) 0.22 (0.05) 0.24 (0.06) (0.03)
Haemorrhage/pulmonary haemorrhage – – – – – – – – 0.16 (0.01) (0) 0.16 (0.02) –
Respiratory disorders – 0.17 (0) – – – – – – – – – 0.20 (0.01)
Cough – 0.06 (0) – – – – – – – – – 0.14 (0.01)
Skin/dermatology disorders – 0.57 (0.01) 0.62 (0.09) – – – – – – – – 0.12 (0)
Rash 0.02 (0) 0.50 (0.01) 0.61 (0.09) (0.11) – 0 (0) 0.02 (0) 0.04 (0) 0.22 (0.01) – 0.63 (0.07) 0.04 (0)
Mucositis/stomatitis 0.07 (0.01) – – (0.11) – 0.16 (0) 0.05 (0.01) – – – – 0.01 (0)
Gastrointestinal disorders – 0.33 (0) 0.23 (0.02) – – – – – – – – 0.10 (0)
Diarrhoea 0.05 (0) 0.25 (0) 0.19 (0.01) – – 0.04 (0.01) 0.04 (0) 0.05 (0.01) 0.20 (0.02) – 0.52 (0.10) 0.03 (0)
Nausea 0.19 (0.01) 0.03 () – – – 0.44 (0) 0.14 (0.01) – 0.12 () 0.23 () – 0.03 (0)
Taste alteration – – – – – 0.20 (0) 0.08 (0) – – – – –
Sensory neuropathy/hypoesthesia 0.09 (0.01) 0.01 () – – – 0.24 (0) 0.05 (0) – – – – 0.05 (0)
Listed in table are adverse events (AEs) that occurred in at least 10% of subjects, full list of AEs with respective conﬁdence intervals is provided in Appendix Table A6–7. Depending on reporting of
trials, treatment-related AEs were used where available.
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Fig. 5. Surface under the cumulative ranking (SUCRA) curve of overall survival by Eastern Cooperative Oncology Group (ECOG) performance
status (PS), histology, and response to induction for maintenance treatments in good performance status stage IIIb/IV non-small-cell lung cancer
(NSCLC) patients not progressing after ﬁrst-line induction. As an illustration (solid line, PS 0 panel), switch to pemetrexed had 63% probability of
being the best maintenance for overall survival (OS) beneﬁt, 85% probability of being among two best maintenance, 94% probability of being
among the three best, and >99% probability of being among the four best, with average of these cumulative rank probabilities represented by
SUCRA 85.4%. Mid-point step intervals were taken for each rank on the x-axis [21]. SUCRA plots by epidermal growth factor receptor (EGFR)
mutation were not illustrated as there were only two treatment comparisons. aSwitch to pemetrexed [39] and continue pemetrexed [9,46] estimates
by performance status (PS) and induction response were estimated from trials results within the nonsquamous population. bTyrosine kinase
inhibitor (TKI) estimates by PS, histology and induction response were in a predominantly Caucasian population.
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